Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 After Sipuleucel-T in mCRPC
NCT01881867Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2013
- Primary completion
- May 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human interleukin-7 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fred Hutchinson Cancer Center. Started Sep 2013; status: completed.
02
Drugs
recombinant human interleukin-7
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01881867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01881867.